AD-MS 芯片用于基于生物流体的阿尔茨海默病诊断-猫眼课题宝

AD-MS 芯片用于基于生物流体的阿尔茨海默病诊断

批准号：

8897940

负责人：

DAOJING WANG

金额：

$35.0万

依托单位：

NEWOMICS, INC

依托单位国家：

美国

项目类别：

财政年份：

2014

资助国家：

美国

项目状态：

已结题

起止时间：

2014-08-01 至 2017-04-30

来源：

https://reporter.nih.gov/project-details/8897940

关键词：

Affect Age All-Trans-Retinol Alzheimer&apos s Disease American Amyloid Amyloid beta-Protein Apolipoprotein A-I Award Binding Bioinformatics Biological Biological Markers Biology Biomedical Research Cerebrospinal Fluid Clinical Clinical Research Clinical Trials Cognition Complex Cysteine Metabolism Pathway Databases Development Diabetes Mellitus Diagnosis Disease Disease Progression Early Diagnosis Early treatment Energy Metabolism FDA approved Functional disorder Future Glucose Half-Life Health Human Length Link Liquid Chromatography Liquid substance Manuscripts Mass Spectrum Analysis Measurement Metabolism Microfluidics Monitor Neurodegenerative Disorders Neurologic Non-Insulin-Dependent Diabetes Mellitus Oxidative Stress Pathway interactions Patients Peptides Phase Plague Plasma Play Positron-Emission Tomography Prealbumin Production Protein Analysis Proteins Proteomics Reactive Oxygen Species Reproducibility Retinol Binding Proteins Sampling Scanning Sensitivity and Specificity Serum Silicon Small Business Innovation Research Grant Specificity Staging Technology Testing Thiamine Thyroid Hormones Thyroxine Validation Vitamin A base clinical application disease diagnosis glucose metabolism glycation innovation insight ionization metabolomics nano-electrospray novel prospective protein metabolite response small molecule targeted treatment

项目摘要

项目成果

DAOJING WANG的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disease that affects more than 35 million people (including 5 million Americans) worldwide, and this number is expected to reach more than 115 million by the year 2050. Recent disappointing clinical trials of bapineuzumab and solanezumab in AD treatment further aggravate the problem. There is currently no definitive biomarker for early diagnosis or therapy of AD. The field is calling for transformative technologies and approaches. In response to PA-11-335, Newomics Inc. proposes to develop integrated silicon microfluidic chips, termed AD-MS chips, as a revolutionary platform for rapid, sensitive, and specific biofluids-based early diagnosis of AD. The core technology will be based on Newomics' breakthrough silicon-microfluidic-chip, the multinozzle emitter array chip (MEA chip-2012 R&D100 award), which enables liquid chromatography-nanoelectrospray ionization mass spectrometry (LC-nanoESI/MS)-based, highly sensitive, highly specific, high-throughput, and multiplex measurements of multiclass analytes (peptides, proteins, and metabolites) at the Omics level, from small volumes of samples. The project is also based on our recent discovery of several proteoforms in human plasma as potential AD biomarkers through top-down proteomics studies using our MEA chips. In this SBIR project, we will develop AD-MS chips as a high-throughput and multiplex multi-omics platform. AD-MS chips will enable high-throughput and multiplex measurements of "multiclass" analytes (peptides, proteins, and metabolites), from small volumes of human plasma and cerebrospinal fluid (CSF) samples, thereby dramatically accelerating the discovery, validation, and clinical application of "Multiclass Biomarker Panel (MBP)" for AD diagnosis. If validated in future prospective clinical studies, AD-MS chips will enable rapid, sensitive, and affordable biofluids-based early diagnosis of AD.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文